PART I . Overview We are a clinical stage biotechnology company fully dedicated to developing IL-1-based treatments for immune-mediated inflammatory diseases. Our lead product candidate, abdakibart (AVTX-009), an anti-IL-1 monoclonal antibody (mAb) is in a Phase 2 clinical trial for hidradenitis suppurativa (HS). We are also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. Our current focus is on completing the Phase 2 (LO...
Q2 FY2026 — expected 2026-09-19
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-23 | 2025-12-31 | 0001534120-26-000011 | EDGAR | 102K words |
| 2025-03-20 | 2024-12-31 | 0001628280-25-013986 | EDGAR | — |
| 2024-03-29 | 2023-12-31 | 0001628280-24-013786 | EDGAR | — |
| 2023-03-29 | 2022-12-31 | 0001628280-23-009630 | EDGAR | — |
| 2022-03-02 | 2021-12-31 | 0001628280-22-004671 | EDGAR | — |
| 2021-03-08 | 2020-12-31 | 0001628280-21-004162 | EDGAR | — |
| 2020-03-11 | 2019-12-31 | 0001628280-20-003395 | EDGAR | — |
| 2019-03-18 | 2018-12-31 | 0001628280-19-003078 | EDGAR | — |
| 2018-04-02 | 2017-12-31 | 0001628280-18-003890 | EDGAR | — |
| 2017-03-14 | 2016-12-31 | 0001628280-17-002566 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001534120-26-000049 | EDGAR | — |
| 2025-11-06 | 2025-09-30 | 0001534120-25-000018 | EDGAR | 23K words |
| 2025-08-07 | 2025-06-30 | 0001628280-25-038575 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001628280-25-024436 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001628280-24-045965 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0001628280-24-036591 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0001628280-24-022763 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001628280-23-038036 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0001628280-23-026990 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001628280-23-015703 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0001628280-22-028538 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001628280-22-020866 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001534120-26-000048 | EDGAR | — |
| 2026-03-27 | 0001534120-26-000016 | EDGAR | 1K words |
| 2026-03-23 | 0001534120-26-000010 | EDGAR | — |
| 2026-01-12 | 0001534120-26-000003 | EDGAR | — |
| 2025-12-02 | 0001534120-25-000022 | EDGAR | — |
| 2025-11-06 | 0001534120-25-000017 | EDGAR | — |
| 2025-10-29 | 0001534120-25-000013 | EDGAR | — |
| 2025-10-10 | 0001534120-25-000011 | EDGAR | — |
| 2025-10-01 | 0001534120-25-000009 | EDGAR | — |
| 2025-09-22 | 0001534120-25-000005 | EDGAR | — |
286 total filings indexed. 254 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001534120 |
| Ticker | AVTX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.avalotx.com |
| Listed | 2015-11-13 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/AVTX (~200 tokens, structured JSON with cryptographic provenance)